
West Pharmaceutical Services, Inc.: updates and filings
Price
$396.69
November 19, 2026Market cap $28.6B
What Ploutos Investor adds for West Pharmaceutical Services
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Oct 29, 2026next Jan 22, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
October 2026
July 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 5, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Oct 29, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Oct 29, 2026Results of operations, Regulation FD disclosureForm8-K
- Oct 26, 2026Material agreement entered, material agreement ended, new material financial obligationForm8-K
- Aug 6, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jul 23, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Jul 23, 2026Results of operations, Regulation FD disclosureForm8-K
- Jul 14, 2026Material agreement enteredForm8-K
- Jun 1, 2026Officer or director change, Regulation FD disclosureForm8-K
- May 20, 2026Material cybersecurity incident (amendment)Form8-K/A
- May 13, 2026Conflict minerals reportFormSD
- May 11, 2026Material cybersecurity incident, Regulation FD disclosureForm8-K
- May 5, 2026Shareholder voteForm8-K
- Apr 30, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 29, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 23, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- Apr 23, 2026Results of operations, Regulation FD disclosureForm8-K
- Mar 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 12, 2026Additional annual meeting materialFormDEFA14A
- Mar 12, 2026Annual meeting proxy statementFormDEF 14A
- Mar 9, 2026Officer or director change, Regulation FD disclosureForm8-K
- Feb 17, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 12, 2026Results of operations, Regulation FD disclosureForm8-K
- Oct 31, 2025Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Oct 23, 2025Quarterly reportfor the period to Sep 30, 2025Form10-Q
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 5, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Oct 29, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Oct 29, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Oct 26, 2026 | 8-K | Material agreement entered, material agreement ended, new material financial obligation | Document |
| Aug 6, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jul 23, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Jul 23, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Jul 14, 2026 | 8-K | Material agreement entered | Document |
| Jun 1, 2026 | 8-K | Officer or director change, Regulation FD disclosure | Document |
| May 20, 2026 | 8-K/A | Material cybersecurity incident (amendment) | Document |
| May 13, 2026 | SD | Conflict minerals report | Document |
| May 11, 2026 | 8-K | Material cybersecurity incident, Regulation FD disclosure | Document |
| May 5, 2026 | 8-K | Shareholder vote | Document |
| Apr 30, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 29, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 23, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| Apr 23, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Mar 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 12, 2026 | DEFA14A | Additional annual meeting material | Document |
| Mar 12, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 9, 2026 | 8-K | Officer or director change, Regulation FD disclosure | Document |
| Feb 17, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 12, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Oct 31, 2025 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Oct 23, 2025 | 10-Q | Quarterly reportfor the period to Sep 30, 2025 | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Feb 11, 1994.
The full analysis
What do West Pharmaceutical Services's filings show?
The filings are where every one of West Pharmaceutical Services's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.